Navigation Links
Zyngenia, Inc. Raises $10 Million in Series A Funding
Date:11/4/2009

ROCKVILLE, Md., Nov. 4 /PRNewswire/ -- Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, today announced that it has secured $10 million in Series A funding from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to create novel, multi-specific antibody-like molecules that address two or more biological targets with a single agent. The company will initially focus on various cancers and autoimmune diseases.

"Zyngenia's technology platform, developed by Carlos Barbas of The Scripps Institute, is very compelling due to its ability to create biologics that are single protein-combination therapeutics in a manner that is likely to be scientifically, medically, and economically transforming," said Peter Kiener, D.Phil., Zyngenia Chief Executive Officer. "With financial support from NEA, we are poised to take a leadership role in the development of multi-specific biologic therapies."

In previous positions at MedImmune and Bristol-Myers Squibb (BMS), Dr. Kiener gained extensive experience in both biologics and small molecule drug discovery across oncology, immunology, infectious disease and other therapeutic areas. During eight years at MedImmune, most recently as Executive Vice President and Head of Research and Development, Dr. Kiener helped to build industry-leading protein and antibody engineering capabilities and oversaw the submission of numerous INDs and BLAs. Dr. Kiener was also responsible for the integration of both the protein/antibody engineering company Cambridge Antibody Technology and the B-cell biologics company Cellective Therapeutics into MedImmune. Prior to joining MedImmune, Dr. Kiener spent 18 years with Bristol-Myers Squibb's Pharmaceutical Research Division.

Carlos F. Barbas, III, Ph.D., Zyngenia's Chief Scientific Officer, is Professor and Chair of the Skaggs Institut
'/>"/>

SOURCE Zyngenia, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Pearl Therapeutics Raises $15.5 Million in Private Financing
2. Enobia Pharma Raises $40.1 Million Series B Financing
3. Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
4. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
5. VisEn Medical Raises $7 Million in Series B Financing
6. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
9. Perrigo Announces Final FDA Approval of Dexcels OTC Omeprazole; Raises Full Year Earnings Guidance
10. Anesiva Raises $45 Million in Common Stock Offering
11. Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. ... for pain has reached an important milestone, as Virobay ... VBY-036 - a selective cathepsin S inhibitor.   ... a double-blind, randomized, placebo-controlled study designed to evaluate the ... VBY-036 in healthy adults. "The initiation of ...
(Date:5/23/2013)... 23, 2013 The New Jersey chapter ... Black Data Processing Associates (BDPA), is hosting its 10th ... 2013. This all-day event will encourage students and their ... ins and outs from many of the industries’ finest ... the New Jersey Institute of Technology, the event will ...
(Date:5/23/2013)... 2013 SynCardia Systems, Inc. ( http://www.syncardia.com ... Health Canada and CE (Europe) approved Total Artificial Heart, ... which boasts more than 380,000 visitors annually, is featuring ... by the Freedom® portable driver as part of its ... exhibitions of its kind. , “BodyWorks combines the ...
(Date:5/23/2013)... Ralph Huber, President of PHI Management Solutions announced ... survival kits would be on sale through Father’s Day. ... executive board meeting on May 22nd. , Huber opened ... tornado victims and used the opportunity to remind all of ... paramount. “When disaster strikes,” he said, “Our customers may ...
Breaking Biology Technology:Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3PHI Emergency Management on Announces Father's Day Specials All Emergency Survival Kits 2
... Calif., May 19, 2011 Isis Pharmaceuticals, Inc. (NASDAQ: ... earned a $5 million milestone payment from GlaxoSmithKline (GSK) ... study for ISIS-TTRRx.  ISIS-TTRRx is designed to treat transthyretin ... slow degeneration of peripheral nerve and/or heart tissues . ...
... Inc. announced today that it has initiated patient enrollment ... lead product candidate TG-C.  TG-C involves human allogeneic chondrocytes ... regeneration of cartilage in patients suffering from severe osteoarthritis ... placebo-controlled Phase II study will evaluate the safety and ...
... NEW YORK, May 18, 2011 Oppenheimer & Co. Inc., ... Matthias Spaenle, MD will join the firm as Managing Director ... he will help to drive its life science business. He ... Healthcare Investment Banking.   Since 2003, Matthias had ...
Cached Biology Technology:Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline 2Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline 3Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline 4TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee 2
(Date:5/23/2013)... natural history museums of the world are billions of ... to flowers, mushrooms and grasses, all stacked, stored and ... and diverse collections could be critical to understanding how ... a growing human footprint if only the information ... to life with the help of a team from ...
(Date:5/22/2013)... (NLST) investigators also conclude that the 20 percent ... tomography (LDCT) versus chest X-ray (CXR) screening previously ... at experienced screening centers in the United States. ... with their patients about the benefits and risks ... in the New England Journal of Medicine ...
(Date:5/22/2013)... new, streamlined approach to genetic engineering drastically reduces ... genes into bacteria, the workhorses of biotechnology, scientists ... Synthetic Biology , the method paves the way ... drug development, environmental cleanup and other activities. , ... integrating, a piece of the genetic material DNA ...
Breaking Biology News(10 mins):CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... one of the great advances of the 19th and 20th ... too wet to farm. In fact, installation of new tile ... yields. But a recent study shows that the most heavily ... source of nitrate to the Gulf of Mexico, leading to ...
... WASHINGTON, Sept. 27 Several thousand federal, state and ... gather at Northern Virginia,s Stafford Regional Airport next May ... technology for countering terrorist threats to personnel, equipment and ... domestic settings within the U.S. and abroad. ...
... findings from an upcoming new report by the International ... poor state of post-fracture care in the Russian Federation ... were announced today at a press conference in St. ... Central Asian Osteoporosis Patient Societies. Osteoporosis, a disease ...
Cached Biology News:Tile drainage directly related to nitrate loss 2Tile drainage directly related to nitrate loss 3Industry to Demonstrate Off-the-Shelf Integrated Force Protection and Counter-Terrorism Solutions at Northern Virginia Site 2Industry to Demonstrate Off-the-Shelf Integrated Force Protection and Counter-Terrorism Solutions at Northern Virginia Site 3High death and disability rates due to fractures in Russia, Central Asia and Eastern Europe 2
...
... the submicron range are part of your ... control of particle size is important to ... reliably detect the component populations in your ... Size Analyzer uses Photon Correlation Spectroscopy (PCS) ...
Experion StdSens chips are the microfluidic chips used to perform standard-sensitivity RNA analysis (nanogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to...
... The Experion system, 100-120 and 220-240 V, ... the steps of gel-based electrophoresis, including some ... configuration is used for protein analysis (it ... for RNA analysis). The system includes the ...
Biology Products: